Xilis Announces Series A Extension, Bringing Total Round to Over US$89 Million

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

Xilis, Inc., a pioneering biotechnology company developing its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, has closed an extension of over US$19 million to its Series A financing round, bringing the total amount raised to over US$89 million.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Wednesday, July 13, 2022
Information
Tags: 
Other Health, Health, Pharmaceutical, Biometrics, Oncology, Other Science, Medical Devices, Research, Hospitals, Science, Clinical Trials, Technology, Mubadala Investment Company, Biotechnology, LinkedIn, Tumor microenvironment, Google Voice, Investment, GV (company), Patient, MOS, Cell Stem Cell, Drug discovery, Probability, COO, Physician, Founder, Traction, Guild Education, FPV, Felicis Ventures, Cancer, Google Analytics, Oncology, Doctor of Philosophy, Financial services, Pharmaceutical industry, GV, Canva, Li Xilie
Geotags: 
UNITED STATES, NORTH AMERICA, NORTH CAROLINA, NEW YORK, BRAZIL, LONDON, SAN FRANCISCO
⚠ generated by AI ↴
Organisation: 
XILIS, FPV, MUBADALA CAPITAL
Summary
Key Points: 
  • Xilis, Inc., a pioneering biotechnology company developing its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, has closed an extension of over US$19 million to its Series A financing round, bringing the total amount raised to over US$89 million.
  • Our MOS technology is the first end-to-end, high-throughput patient-derived model drug discovery platform to identify drug candidates with a high probability of clinical success.
  • The company will use the Series A funding to advance its proprietary MOS platform.
  • Using MOS and AI-driven algorithms, Xilis is developing a Xilis Response Score for the clinic, enabling oncologists to make informed and timely treatment decisions.


Xilis, Inc., a pioneering biotechnology company developing its MicroOrganoSphere™ (MOS™) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, has closed an extension of over US$19 million to its Series A financing round, bringing the total amount raised to over US$89 million. New investor FPV Ventures led the extension, with participation from fellow new investor Alexandria Venture Investments and existing investors EQT Life Sciences, Mubadala Capital Management, Pear Ventures, GV (formerly Google Ventures), the Duke Angel Network, Catalio Capital Management, Two Sigma Ventures, Felicis Ventures, Alix Ventures and other strategic partners.

“Despite unprecedented market conditions in the biotech sector, we raised this extension at a step-up valuation and from several of the most reputable global investors. Our investors are strongly encouraged by the progress we have made in building diagnostic programs that predict patient response and achieving significant traction in partnered drug discovery and development,” said Xiling Shen, PhD, Founder and Chief Executive Officer of Xilis. “Our MOS technology is the first end-to-end, high-throughput patient-derived model drug discovery platform to identify drug candidates with a high probability of clinical success.”

The company will use the Series A funding to advance its proprietary MOS platform. This innovative MOS technology is the first truly scalable patient-derived model that recapitulates the tumor microenvironment and immune interactions necessary for next-generation immuno-oncology and cell therapy drug discovery. In addition, the MOS platform can be applied in a clinical setting to aid clinicians to make precision oncology treatment decisions, identifying treatments that lead to the best response for each patient.

“Xilis has pushed forward and achieved meaningful scientific breakthroughs that will change the way cancer drugs are being discovered and how patients are being selected to achieve the most optimal response – realizing the goal of personalized precision oncology,” said Wesley Chan, Co-Founder & Managing Partner of FPV Ventures. “With support from a world-class investor consortium, Xilis is set to continue its efforts in clinical diagnostics and accelerate the company’s growth by expanding its MOS technology into biopharma R&D and drug development.”

Recently, the company announced its participation in the Netherlands-based Oncode-PACT Consortium to accelerate the development of cancer drugs and was selected as the cover article/story in the June issue of the journal Cell Stem Cell highlighting its MOS technology and application in precision oncology.

“Over the last year, Xilis has made tremendous progress in advancing their MOS platform, demonstrating its value both for physicians and biopharma partners, while addressing the significant challenges faced with precision and predictability in cancer treatments,” said Ayman AlAbdallah, Partner, Mubadala Capital. “As Mubadala continues to support companies across their entire life cycle, we are excited to back Xilis once again in their work toward impacting the future of healthcare.”

About Xilis

Based in Durham, North Carolina, Xilis, Inc. is a biotechnology company developing a precision oncology platform that guides treatment decisions for oncologists to improve cancer care outcomes for patients and enables drug discovery and development with pharmaceutical companies. Xilis’ proprietary MicroOrganoSphere™ (MOS) technology consists of miniature patient tumors that capture the full microenvironment and heterogeneity and provides an automated and scalable solution. Using MOS and AI-driven algorithms, Xilis is developing a Xilis Response Score™ for the clinic, enabling oncologists to make informed and timely treatment decisions. Additionally, the MOS technology is speeding up the discovery and clinical development of new drug candidates.

To learn more about Xilis, visit our website at Xilis.com or follow us on LinkedIn.

About FPV

FPV is a new $450m fund focused on backing and serving mission-driven founders throughout their entire journey. Founded by Wesley Chan (Founder of Google Analytics and Google Voice) and Pegah Ebrahimi (former COO of Morgan Stanley Tech Banking and COO of Cisco Collaboration), the firm has backed well-known, high-impact startups including Canva, Flexport, Guild Education, Xilis, and Manifold Bio.

About Mubadala Capital

Mubadala Capital is the wholly owned asset management arm of Mubadala Investment Company. Since its inception a decade ago, Mubadala Capital has grown to become a global asset manager of significant scale, with over US $16 billion of assets under management and a presence in London, New York, San Francisco, Rio de Janeiro, and headquarters in Abu Dhabi. Through its four businesses, Mubadala Capital manages over US $10 billion in third-party capital vehicles on behalf of its institutional investors, including three private equity funds, two early stage venture funds, a public equities fund, and two funds in Brazil focused on special situations.

Copyright: 
Copyright Business Wire 2022